US Biosecure Act set to pass, Beijing’s response uncertain
Subscribe to keep reading.
Sign up to stay briefed on what the Chinese government is doing, thinking, and saying.
Already a subscriber? Log in.
The US Biosecure Act – which could exclude drugmakers from US federal contracts if they work with certain Chinese biotechnology firms – is set to become law.
It's folded into the 2026 US National Defense Authorization Act (NDAA), which is bound for US President Donald Trump's desk and widely expec...